Join Growin Stock Community!

Greenwich lifesciences, inc.GLSI.US Overview

US StockHealthcare
(No presentation for GLSI)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GLSI AI Insights

GLSI Overall Performance

GLSI AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GLSI Recent Performance

1.91%

Greenwich lifesciences, inc.

0.05%

Avg of Sector

-0.31%

S&P500

GLSI PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GLSI Key Information

GLSI Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GLSI Profile

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Price of GLSI

GLSI FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GLSI Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
175.77
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
175.77
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is GLSI's latest earnings report released?

    The most recent financial report for Greenwich lifesciences, inc. (GLSI) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GLSI's short-term business performance and financial health. For the latest updates on GLSI's earnings releases, visit this page regularly.

  • How much cash does GLSI have?

    At the end of the period, Greenwich lifesciences, inc. (GLSI) held Total Cash and Cash Equivalents of 3.81M, accounting for 1 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is GLSI's EPS continuing to grow?

    According to the past four quarterly reports, Greenwich lifesciences, inc. (GLSI)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.3. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GLSI?

    Greenwich lifesciences, inc. (GLSI)'s Free Cash Flow (FCF) for the period is -2.67M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 3.38% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.